Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Next Previous
Trial Profile

Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obicetrapib (Primary)
  • Indications Atherosclerosis; Cerebrovascular disorders; Coronary artery disease; Myocardial infarction; Peripheral arterial disorders; Stroke
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PREVAIL; PREVAIL CVOT
  • Sponsors NewAmsterdam Pharma

Most Recent Events

  • 09 May 2024 Status changed from recruiting to active, no longer recruiting.
  • 10 Apr 2024 According to a NewAmsterdam Pharma media release, Stephen Nicholls, Ph.D., Director, Monash Victorian Heart Institute and Professor of Cardiology, Monash University is the primary investigator on the Phase 3 PREVAIL trial.
  • 10 Apr 2024 According to a NewAmsterdam Pharma media release, today announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL and enrollment to continue to the end of April to accommodate strong patient and site interest.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top